astemizole

Ligand id: 2603

Name: astemizole

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 42.32
Molecular weight 458.25
XLogP 6.61
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Approved drug? Yes
Withdrawn drug? Yes
IUPAC Name
1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]benzimidazol-2-amine
International Nonproprietary Names
INN number INN
4755 astemizole
Synonyms
Hismanal®
Database Links
BindingDB Ligand 24226
CAS Registry No. 68844-77-9
ChEBI CHEBI:2896
ChEMBL Ligand CHEMBL296419
DrugBank Ligand DB00637
PubChem CID 2247
Search Google for chemical match using the InChIKey GXDALQBWZGODGZ-UHFFFAOYSA-N
Search Google for chemicals with the same backbone GXDALQBWZGODGZ
Search PubMed clinical trials astemizole
Search PubMed titles astemizole
Search PubMed titles/abstracts astemizole
Search UniChem for chemical match using the InChIKey GXDALQBWZGODGZ-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone GXDALQBWZGODGZ
Wikipedia Astemizole
Comments
Astemizole was originally identified as a histamine H1 receptor antagonist. Astemizole use as an antihistamine was withdrawn from the US market in 1999 as it caused arrhythmias, probably due to blocking the hERG potassium channel (Kv11.1) [5].

A 2014 publication showed that astemizole's anti-proliferative effects in cancer cells is due to disruption of a protein-protein interaction required for the formation of the active polycomb repressive complex 2 (PRC2) [3]. PRC2 contains the histone methyltransferase EZH2, which is responsible for catalytic trimethylation of lysine 27 on histone H3 (H3K27me3), an epigenetic modification that is a hallmark of silent chromatin. Aberrant PRC2 activity is associated with cancer initiation and progression. Astemizole was shown to inhibit the interaction between EZH2 and a PRC2 structural protein called embryonic ectoderm development (EED) [1], and that this action destabilizes PRC2 and reduces its methylation activity.